Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$24.55
0.010.04%
Pre-Market: 5:20 AM EDT
Comments
Loading...
Pfizer Analyst Ratings and Price Targets | NYSE:PFE | Benzinga
Pfizer Inc has a consensus price target of $35.86 based on the ratings of 23 analysts. The high is $50 issued by HSBC on July 14, 2023. The low is $25 issued by Wolfe Research on November 15, 2024. The 3 most-recent analyst ratings were released by Guggenheim, UBS, and Citigroup on February 10, 2025, February 5, 2025, and January 28, 2025, respectively. With an average price target of $30 between Guggenheim, UBS, and Citigroup, there's an implied 22.20% upside for Pfizer Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Citigroup
Truist Securities
B of A Securities
Wolfe Research
1calculated from analyst ratings
Analyst Ratings for Pfizer
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | — | Guggenheim | Vamil Divan75% | — | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | — | Guggenheim | Vamil Divan75% | — | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | 34.42% | Guggenheim | Vamil Divan75% | $33 → $33 | Reiterates | Buy → Buy | Get Alert |
| 02/05/2025 | Buy Now | 14.05% | UBS | Colin Bristow42% | $29 → $28 | Maintains | Neutral | Get Alert |
| 01/28/2025 | Buy Now | 18.13% | Citigroup | Andrew Baum71% | $30 → $29 | Maintains | Neutral | Get Alert |
| 01/08/2025 | Buy Now | 18.13% | UBS | Colin Bristow42% | $31 → $29 | Maintains | Neutral | Get Alert |
| 12/18/2024 | Buy Now | 30.35% | Truist Securities | Srikripa Devarakonda47% | $36 → $32 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | 34.42% | Guggenheim | Vamil Divan75% | $35 → $33 | Maintains | Buy | Get Alert |
| 12/10/2024 | Buy Now | 18.13% | B of A Securities | Tim Anderson54% | → $29 | Reinstates | → Neutral | Get Alert |
| 11/15/2024 | Buy Now | 1.83% | Wolfe Research | Alexandria Hammond47% | → $25 | Initiates | → Underperform | Get Alert |
| 10/30/2024 | Buy Now | 26.27% | Morgan Stanley | Terence Flynn66% | $30 → $31 | Maintains | Equal-Weight | Get Alert |
| 10/25/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 10/23/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 10/17/2024 | Buy Now | 30.35% | Bernstein | Courtney Breen1% | → $32 | Initiates | → Market Perform | Get Alert |
| 10/11/2024 | Buy Now | 22.2% | Morgan Stanley | Terence Flynn66% | $31 → $30 | Maintains | Equal-Weight | Get Alert |
| 10/03/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 08/08/2024 | Buy Now | 38.49% | Daiwa Capital | Narumi Nakagiri23% | $28 → $34 | Upgrade | Neutral → Outperform | Get Alert |
| 07/31/2024 | Buy Now | 26.27% | Morgan Stanley | Terence Flynn66% | $29 → $31 | Maintains | Equal-Weight | Get Alert |
| 07/31/2024 | Buy Now | 30.35% | Barclays | Carter Gould58% | $30 → $32 | Maintains | Equal-Weight | Get Alert |
| 07/31/2024 | Buy Now | 22.2% | Wells Fargo | Mohit Bansal72% | $28 → $30 | Maintains | Equal-Weight | Get Alert |
| 07/31/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 07/31/2024 | Buy Now | 26.27% | UBS | Colin Bristow42% | $30 → $31 | Maintains | Neutral | Get Alert |
| 07/12/2024 | Buy Now | 22.2% | UBS | Colin Bristow42% | $28 → $30 | Maintains | Neutral | Get Alert |
| 07/10/2024 | Buy Now | 22.2% | Barclays | Carter Gould58% | $28 → $30 | Maintains | Equal-Weight | Get Alert |
| 07/10/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 07/01/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 05/02/2024 | Buy Now | 18.13% | Morgan Stanley | Terence Flynn66% | $28 → $29 | Maintains | Equal-Weight | Get Alert |
| 05/02/2024 | Buy Now | 46.64% | BMO Capital | Evan David Seigerman52% | $33 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 04/18/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/15/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/05/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/31/2024 | Buy Now | 18.13% | Morgan Stanley | Terence Flynn66% | $28 → $29 | Maintains | Equal-Weight | Get Alert |
| 03/22/2024 | Buy Now | — | Argus Research | David Toung71% | — | Downgrade | Buy → Hold | Get Alert |
| 03/04/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/01/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 46.64% | Guggenheim | Vamil Divan75% | → $36 | Initiates | → Buy | Get Alert |
| 01/31/2024 | Buy Now | 14.05% | UBS | Colin Bristow42% | $29 → $28 | Maintains | Neutral | Get Alert |
| 01/31/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 01/17/2024 | Buy Now | 18.13% | UBS | Colin Bristow42% | $27 → $29 | Maintains | Neutral | Get Alert |
| 01/09/2024 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 01/04/2024 | Buy Now | 30.35% | TD Cowen | Steve Scala69% | → $32 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/14/2023 | Buy Now | 14.05% | Wells Fargo | Mohit Bansal72% | $35 → $28 | Maintains | Equal-Weight | Get Alert |
| 12/14/2023 | Buy Now | 83.3% | Cantor Fitzgerald | Louise Chen57% | $75 → $45 | Maintains | Overweight | Get Alert |
| 12/14/2023 | Buy Now | 46.64% | Truist Securities | Robyn Karnauskas55% | $42 → $36 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 9.98% | UBS | Colin Bristow42% | $34 → $27 | Maintains | Neutral | Get Alert |
| 12/14/2023 | Buy Now | 14.05% | Barclays | Carter Gould58% | $34 → $28 | Maintains | Equal-Weight | Get Alert |
| 12/04/2023 | Buy Now | 71.08% | Truist Securities | Robyn Karnauskas55% | → $42 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 11/01/2023 | Buy Now | 38.49% | Barclays | Carter Gould58% | $35 → $34 | Maintains | Equal-Weight | Get Alert |
| 11/01/2023 | Buy Now | 50.71% | Morgan Stanley | Terence Flynn66% | $39 → $37 | Maintains | Equal-Weight | Get Alert |
| 10/20/2023 | Buy Now | 38.49% | UBS | Colin Bristow42% | $36 → $34 | Assumes | Neutral → Neutral | Get Alert |
| 10/17/2023 | Buy Now | 71.08% | Truist Securities | Robyn Karnauskas55% | $62 → $42 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | 58.86% | Morgan Stanley | Terence Flynn66% | $40 → $39 | Maintains | Equal-Weight | Get Alert |
| 10/17/2023 | Buy Now | 42.57% | Wells Fargo | Mohit Bansal72% | $39 → $35 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 34.42% | BMO Capital | Evan David Seigerman52% | $44 → $33 | Maintains | Outperform | Get Alert |
| 10/16/2023 | Buy Now | 42.57% | Citigroup | Andrew Baum71% | $42 → $35 | Maintains | Neutral | Get Alert |
| 10/16/2023 | Buy Now | 38.49% | JP Morgan | Chris Schott61% | $36 → $34 | Maintains | Neutral | Get Alert |
| 10/16/2023 | Buy Now | 42.57% | Wells Fargo | Mohit Bansal72% | $39 → $35 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 58.86% | Jefferies | Akash Tewari45% | $38 → $39 | Upgrade | Hold → Buy | Get Alert |
| 10/06/2023 | Buy Now | 46.64% | JP Morgan | Chris Schott61% | $39 → $36 | Maintains | Neutral | Get Alert |
| 10/02/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 09/18/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 152.55% | Truist Securities | Robyn Karnauskas55% | → $62 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/30/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2023 | Buy Now | 152.55% | Truist Securities | Robyn Karnauskas55% | $64 → $62 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 62.93% | Morgan Stanley | Terence Flynn66% | $42 → $40 | Maintains | Equal-Weight | Get Alert |
| 08/02/2023 | Buy Now | 79.23% | BMO Capital | Evan David Seigerman52% | $45 → $44 | Maintains | Outperform | Get Alert |
| 07/21/2023 | Buy Now | 71.08% | Morgan Stanley | Terence Flynn66% | $43 → $42 | Maintains | Equal-Weight | Get Alert |
| 07/14/2023 | Buy Now | 103.67% | HSBC | Rajesh Kumar65% | → $50 | Initiates | → Buy | Get Alert |
| 07/11/2023 | Buy Now | 75.15% | Morgan Stanley | Terence Flynn66% | $43 → $43 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/11/2023 | Buy Now | 54.79% | Barclays | Carter Gould58% | $40 → $38 | Maintains | Equal-Weight | Get Alert |
| 06/29/2023 | Buy Now | 62.93% | Credit Suisse | Trung Huynh69% | $47 → $40 | Downgrade | Outperform → Neutral | Get Alert |
| 06/23/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | $75 → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 06/22/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 05/17/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 05/11/2023 | Buy Now | 54.79% | Daiwa Capital | Narumi Nakagiri23% | $51 → $38 | Downgrade | Outperform → Neutral | Get Alert |
| 05/03/2023 | Buy Now | 91.45% | Credit Suisse | Trung Huynh69% | $50 → $47 | Maintains | Outperform | Get Alert |
| 05/03/2023 | Buy Now | 62.93% | Barclays | Carter Gould58% | $43 → $40 | Maintains | Equal-Weight | Get Alert |
| 04/21/2023 | Buy Now | 83.3% | B of A Securities | Geoff Meacham63% | $50 → $45 | Maintains | Neutral | Get Alert |
| 04/12/2023 | Buy Now | 75.15% | Barclays | Carter Gould58% | $44 → $43 | Maintains | Equal-Weight | Get Alert |
| 04/10/2023 | Buy Now | 79.23% | Morgan Stanley | Terence Flynn66% | $45 → $44 | Maintains | Equal-Weight | Get Alert |
| 03/17/2023 | Buy Now | 79.23% | Wells Fargo | Mohit Bansal72% | $50 → $44 | Maintains | Equal-Weight | Get Alert |
| 03/06/2023 | Buy Now | 75.15% | Jefferies | Akash Tewari45% | → $43 | Initiates | → Hold | Get Alert |
| 02/07/2023 | Buy Now | 107.74% | Daiwa Capital | Narumi Nakagiri23% | → $51 | Upgrade | Neutral → Outperform | Get Alert |
| 02/01/2023 | Buy Now | 83.3% | Morgan Stanley | Terence Flynn66% | $53 → $45 | Maintains | Equal-Weight | Get Alert |
| 02/01/2023 | Buy Now | 205.5% | Cantor Fitzgerald | Louise Chen57% | → $75 | Reiterates | → Overweight | Get Alert |
| 02/01/2023 | Buy Now | 103.67% | Credit Suisse | Trung Huynh69% | $54 → $50 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 115.89% | BMO Capital | Evan David Seigerman52% | $55 → $53 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 79.23% | Barclays | Carter Gould58% | $49 → $44 | Maintains | Equal-Weight | Get Alert |
| 02/01/2023 | Buy Now | 87.37% | Atlantic Equities | Steve Chesney56% | $50 → $46 | Maintains | Neutral | Get Alert |
| 02/01/2023 | Buy Now | 95.52% | SVB Leerink | David Risinger73% | $49 → $48 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Pfizer (PFE) stock?
The latest price target for Pfizer (NYSE:PFE) was reported by Guggenheim on March 18, 2025. The analyst firm set a price target for $0.00 expecting PFE to fall to within 12 months (a possible -100.00% downside). 37 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pfizer (PFE)?
The latest analyst rating for Pfizer (NYSE:PFE) was provided by Guggenheim, and Pfizer reiterated their buy rating.
When was the last upgrade for Pfizer (PFE)?
The last upgrade for Pfizer Inc happened on August 8, 2024 when Daiwa Capital raised their price target to $34. Daiwa Capital previously had a neutral for Pfizer Inc.
When was the last downgrade for Pfizer (PFE)?
The last downgrade for Pfizer Inc happened on March 22, 2024 when Argus Research changed their price target from N/A to N/A for Pfizer Inc.
When is the next analyst rating going to be posted or updated for Pfizer (PFE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating Pfizer (PFE) correct?
While ratings are subjective and will change, the latest Pfizer (PFE) rating was a reiterated with a price target of $0.00 to $0.00. The current price Pfizer (PFE) is trading at is $24.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.